Patent ID: 7655644

Claim:
A method for treating a subject suffering from schizophrenia which comprises administering to the subject in need thereof a therapeutically effective amount of a compound of the formula I: wherein: both p's are either 1 or 2 to form an azetidine or a piperidine ring: R 1 is C 3-6 cycloalkyl, cyclopropylmethyl or heterocycle where the heterocycle is a five-membered unsaturated ring containing 1, 2, 3 or 4 heteroatoms chosen from O, N or S, at most one heteroatom being O or S, or a six-membered unsaturated ring containing 1, 2 or 3 nitrogen atoms, R 1 being optionally substituted by halogen or hydroxyl; R 2 is selected from: (1) phenyl, which is substituted with R 2a , R 2b and R 2c , (2) heterocycle, which is substituted with R 2a , R 2b and R 2c , (3) C 1-8 alkyl, which is unsubstituted or substituted with 1-6 halogen, hydroxy, —NR 10 R 11 , phenyl or heterocycle, where the phenyl or heterocycle is substituted with R 2a , R 2b and R 2c , and where R 10 and R 11 are independently selected from: (a) hydrogen, (b) —C 1-6 alkyl, which is unsubstituted or substituted with hydroxy, 1-6 fluoro or —NR 12 R 13 , where R 12 and R 13 are independently selected from hydrogen and —C 1-6 alkyl, (c) —C 3-6 cycloalkyl, which is unsubstituted or substituted with hydroxy, 1-6 fluoro or —NR 12 R 13 , (d) benzyl, and (e) phenyl, (4) C 3-6- 6cycloalkyl, which is unsubstituted or substituted with 1-6 halogen, hydroxy or —NR 10 R 11 , and (5) —C 1-6 alkyl-(C 3-6 cycloalkyl), which is unsubstituted or substituted with 1-6 halogen, hydroxy or —NR 10 R 11 ; R 2a , R 2b and R 2c are independently selected from: (1) hydrogen, (2) halogen, (3) —C 1-6 alkyl, which is unsubstituted or substituted with: (a) 1-6 halogen, (b) phenyl, (c) C 3-6 cycloalkyl, or (d) —NR 10 R 11 , (4) —O—C 1-6 alkyl, which is unsubstituted or substituted with 1-6 halogen, (5) hydroxy, (6) —SCF 3 , (7) —SCHF 2 , (8) —SCH 3 , (9) —CO 2 R 9 , wherein R 9 is independently selected from: (a) hydrogen, (b) —C 1-6 alkyl, which is unsubstituted or substituted with 1-6 fluoro, (c) benzyl, and (d) phenyl, (10) —CN, (11) —SO 2 R 9 , (12) —SO 2 -NR 10 R 11 , (13) —NR 10 R 11 , (14) —CONR 10 R 11 , and (15) —NO 2 ; R 3 is a heterocycle, which is substituted with R 2a , R 2b and R 2c ; R 4 and R 5 are independently selected from: (1) hydrogen, and (2) C 1-6 alkyl, which is unsubstituted or substituted with halogen or hydroxyl, or R 4 and R 5 taken together form a C 3-6 cycloalkyl ring: A is selected from: (1) —O—, and (2) —NR 10 ; m is zero or one, whereby when m is zero, R 2 is attached directly to the carbonyl; or a pharmaceutically acceptable salt thereof.